GH Research PLC Ordinary Shares
N/A
USD
N/A
N/A
...
Chart
Financials
Description
GHRS Company Description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
GHRS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view GHRS Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of GHRS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by GHRS's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of GHRS in WallStreetBets Daily Discussion
GHRS News
Recent insights relating to GHRS
CNBC Recommendations
Recent picks made for GHRS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in GHRS
Corporate Flights
Flights by private jets registered to GHRS
Our Analysis